Developments in molecular biology, especially the development of comprehensive instrumentation, have revealed the existence of a common molecular mechanism among different diseases. For example, a group of diseases called “Repeat expansion disease”, in which abnormal repetition of the same DNA sequence is observed, includes more than 10 diseases with different names, such as Huntington’s disease and muscular dystrophy.

When we discover a drug that showed efficacy in a disease based on molecular-level data, there is the possibility that the discovered drug will show efficacy in multiple disease groups that are common to the molecular-level mechanism. To pursue this possibility, we are conducting “umbrella drug discovery” to explore the drug efficacy of a single drug for multiple diseases.

“Umbrella Drug Discovery” enables efficient and rapid discovery and development of drug seeds for different diseases with a common molecular mechanism.
At present, we are demonstrating the effectiveness of this strategy by applying it to the resistance to multiple anti-cancer drugs and a group of diseases called TDP 43protein-opathy. (See “Piplines” page)

Our company is an academy-based venture, and during our time at the academy, we conducted joint research with almost all of the pharmaceutical companies in Japan. Through this process, we learned about the “pains” of pharmaceutical companies and had the opportunities to solve them. As a result of our efforts to solve these problems, we now hold different patents.
Furthermore, by combining these patents, we have completed our own “drug repositioning platform”.

Partners that have formed strategic alliances with our company can utilize freely our “drug repositioning platform and fundamental technologies” under licenses issued by our company.